Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator.
Autoimmune MRL/1 mice were treated with a recently developed substance with immunomodulating properties, LS-2616. Treatment was initiated at the age of 8 weeks, before the onset of clinically apparent disease, and at 16 weeks of age, after development of established lupus disease. Beneficial therapeutic effects were obtained, even when LS-2616 was administered at the lowest dose tested (1 mg/mouse/week) to 16-week-old mice. The effects of LS-2616 on longevity, as well as on development of lymphadenopathy, splenomegaly, glomerulonephritis, and vasculitis, were pronounced and were comparable with those of cyclophosphamide. The results obtained suggest a potential role for LS-2616 in the treatment of autoimmune disease in humans.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005260:Female; D005921:Glomerulonephritis / Q000473:pathology; D006912:Hydroxyquinolines / Q000627:therapeutic use*; D007109:Immunity / Q000187:drug effects; D008206:Lymphatic Diseases / Q000473:pathology; D051379:Mice; D008815:Mice, Inbred Strains / Q000276:immunology*; D013163:Splenomegaly / Q000473:pathology; D014657:Vasculitis / Q000473:pathology
D000276:Adjuvants, Immunologic; D006912:Hydroxyquinolines; C045282:roquinimex; D003520:Cyclophosphamide